Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SCORE

Financiado

Cerrado

Swift COronavirus therapeutics REsponse

Coronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the sam... ver más

30/09/2022

Leiden University...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-09-30

SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinica...

I+D

Cerrada hace 4 años

0% 98% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

Leiden University Medical Ce...

449.38K€ | Lider

KU Leuven

681.56K€ | Participante

UZL

325.00K€ | Participante

JANSSEN PHARMACEUTICA NV

51.49K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MAD-CoV 2 Modern approaches for developing antivirals against SARS CoV... 6M€ Cerrado

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

PID2021-127496NB-I00 ANALISIS DE LAS BASES MOLECULARES DE LA INTERACCION SARS-COV... 133K€ Cerrado

VISION Virus Inhibition by siRNA Optimized by NMR 150K€ Cerrado

BIO2011-24333 CARACTERIZACION ESTRUCTURAL DE VIRUS RNA. UNA HERRAMIENTA PA... 339K€ Cerrado

Inhibicov Hit-to-Lead Development of potent broad-spectrum coronavirus... 150K€ Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2020-04-08
Fecha Fin: 2022-09-30

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Coronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the same or a modified form. More than vaccines and therapeutic antibodies, antiviral drugs can target highly conserved viral functions and have the broad-spectrum activity that is critical to combat current and future outbreaks. Since the 2003 SARS outbreak, as leading academic coronavirus researchers, we have collaborated to understand and inhibit coronavirus replication. We defined viral key functions, developed tools for inhibitor screening, and identified/engineered drug candidates. Until 2015, our collaborative efforts were supported by the FP7 SILVER project, but they have been continued until this very day. As European coronavirus experts, we now propose the SCORE project, supported by a leading pharmaceutical company. Virologists, biochemists, structural biologists, and medicinal chemists will collaborate in a state-of-the-art drug discovery/design program that targets 2019-nCoV. Our vast SARS-CoV-derived expertise and unique toolbox will be a major asset to achieve immediate impact. We will target the virus using 5 independent approaches: (i) using of (combinations of) FDA-approved drugs, (ii) targeting viral RNA synthesis, (iii) inhibiting coronavirus proteases, (iv) blocking virus entry, (v) discovery and development of new antivirals. This program will be supplemented with 2019-nCoV toolbox and animal model development. We aim to deliver proof-of-concept for selected compounds within 6-9 months, after which they will be offered for further use/development. This will contribute to short-term solutions for the on-going crisis and also pave the way for mid/long-term success in developing inhibitors that will be active against (evolving) 2019-nCoV strains, other SARS-like coronaviruses, and potentially (beta)coronaviruses at large.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores